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Effect of permanent right internal mammary
artery occlusion on right coronary artery
supply: A randomized placebo-controlled
clinical trial
Marius R. Bigler, Michael Stoller, Christine Tschannen, Raphael Grossenbacher, and Christian Seiler, 3010 Bern,
SwitzerlandBackground Natural, nonsurgical internal mammary artery (IMA) bypasses to the coronary circulation have been
shown to function as extracardiac sources of myocardial blood supply. The goal of this randomized, placebo-controlled,
double-blind trial was to test the efficacy of permanent right IMA (RIMA) device occlusion on right coronary artery (RCA)
occlusive blood supply and on clinical and electrocardiographic (ECG) signs of myocardial ischemia.
Methods This was a prospective superiority trial in 100 patients with chronic coronary artery disease randomly allocated
(1:1) to RIMA vascular device occlusion (verum group) or to RIMA sham procedure (placebo group). The primary study end
point was RCA collateral flow index (CFI) as obtained during a 1-minute ostial RCA balloon occlusion at baseline before and at
follow-up examination 6 weeks after the trial intervention. CFI is the ratio between simultaneous mean coronary occlusive
divided by mean aortic pressure both subtracted by central venous pressure. Simultaneously obtained secondary study end
points were the registration of angina pectoris and quantitative intracoronary ECG ST-segment shift.
Results CFI change during the follow-upperiodwas+0.036 ± 0.068 in the verumgroupand−0.021 ± 0.097 in the placebo
group (P = .0011). Angina pectoris during the same RCAballoon occlusions haddisappeared at follow-up in 14/49patients of the
verum group and in 4/49 patients of the placebo group (P = .0091). Simultaneous intracoronary ECG ST-segment shift change
revealed diminished myocardial ischemia at follow-up in the verum group and more severe ischemia in the placebo group.
Conclusions Permanent RIMA device occlusion augments RCA supply to the effect of diminishing clinical and
electrocardiographic signs of myocardial ischemia during a brief controlled coronary occlusion. (Am Heart J 2020;230:1-2.)Cardiovascular disease is the leading global cause of
death, accounting for more than 17.6 million deaths per
year in 2016, a number expected to grow to more than
23.6 million by 2030.1 In the event of acute coronary
syndrome, percutaneous coronary intervention (PCI) has
been shown efficacious on outcome.2 Conversely, PCI
has not yet been proven beneficial on the course of
chronic stable coronary artery disease (CAD).3
Recent guidelines on myocardial revascularization state
that “prognostic and symptomatic benefits of myocardialrom the and Department of Cardiology, Inselspital, Bern University Hospital, University of
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revascularization critically depend on the completeness
of revascularization,”4 the statement of which is based on
the adverse relationship between extent of myocardial
ischemia and outcome.5,6 Among patients with stable
CAD undergoing coronary angiography, myocardial
revascularization has been documented incomplete in
more than one fourth (138 of 493 patients in the study by
Williams et al7), in whom all-cause mortality has been
found elevated to 5% per year.7 Thus, novel treatment
strategies for patients with incomplete revascularization
are sought for aimed at reducing myocardial ischemia and
angina pectoris, and consequently improving prognosis
of stable CAD.
In the event of coronary occlusion, myocardial
ischemia is mostly influenced by its duration and the
presence or lack of alternative sources of blood supply to
the ischemic region (collateral supply).8 Alternative
sources of coronary blood supply consist of intercoronary
anastomoses, that is, the coronary collateral circulation,
whose benefit on survival has been demonstrated in
chronic CAD.9 Extracardiac coronary blood supply via
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December 2020the internal mammary arteries (IMAs) as natural, that is,
native nonsurgical bypasses, has been described anatom-
ically and conceptually10-13 but not thoroughly examined
for efficacy as a new therapeutic option. As proof of
concept, our group has provided first evidence of
myocardial ischemia–reducing extracardiac coronary
artery supply during temporary as well as permanent
IMA occlusion.14,15
Thus, the present randomized controlled clinical trial
was designed to assess the effect of permanent right IMA
(RIMA) device occlusion versus placebo on right
coronary artery (RCA) occlusive blood supply (collateral
flow index, CFI) and on clinical and electrocardiographic
(ECG) signs of myocardial ischemia.
Methods
Study design and patients
This was a prospective, double-blind, placebo-
controlled clinical trial with 1:1 randomized allocation
to RIMA device occlusion (verum group) or RIMA sham
procedure (placebo group) in 100 patients with chronic
CAD undergoing diagnostic coronary angiography due to
chest pain and diagnosed with RCA stenosis (Figure 1).
The primary study end point was the intergroup
difference in coronary collateral function 6 weeks after
RIMA occlusion or sham procedure (difference in CFI;
see below for calculation) as obtained during a single
artificial, 1-minute ostial RCA balloon occlusion. Second-
ary study end points were changes during follow-up in
angina pectoris and the quantitatively determined intra-
coronary (ic) ECG ST-segment shift during the identical 1-
minute coronary occlusion. Criteria for study inclusion
were age > 18 years, 1- to 3-vessel chronic stable CAD,
and written informed consent for trial participation.
Exclusion criteria were acute coronary syndrome,
previous myocardial infarction in the vascular region
undergoing CFI measurement, prior surgical coronary
bypass, and severe hepatic or renal failure (creatinine
clearance <15 mL/min/1.73 m2).
The study was approved by the ethics committee of the
Kanton of Bern, Switzerland (KEK 360/15), and all
patients gave written informed consent to participate
before the start of the baseline invasive examination.
This work was supported by the Swiss National Science
Foundation (to C. S., grant number 32003B_163256).
The authors are solely responsible for the design and
conduct of this study, all study analyses, the drafting and
editing of the paper, and its final contents.
Cardiac catheterization and coronary angiography
Patients underwent left heart catheterization and
coronary angiography for diagnostic purposes from the
right radial artery approach via a 6-in-5F introducer
sheath. Biplane coronary angiography was performed
followed by left ventriculography. Coronary arterystenoses were assessed quantitatively as percent diameter
reduction using the guiding catheter for calibration.
Aortic pressure (Pao) was acquired via a 6F guiding
catheter. Central venous pressure (CVP) was measured by
a 5F pigtail catheter as right atrial pressure via the right
femoral vein.
Randomization and masking
Randomized, computer-based allocation to the RIMA
device occlusion or placebo group occurred after
diagnostic coronary angiography and was stratified
according to the clinical decision on whether or not
PCI in the left coronary artery territory could be deferred
until invasive follow-up examination at 6 weeks after
study inclusion. PCI of the RCA was deferred in all but 4
patients in whom RCA stenosis was subtotal (2 patients in
each group). Patients were not informed about group
allocation until completion of all the follow-up study end
point measurements. Naturally, the interventional oper-
ator was not blinded for the study procedure at baseline,
nor was he blinded at follow-up examination because the
device was instantaneously visible already during fluo-
roscopy. At the time of data analysis, the analyzing
operator was unaware of a patient's group allocation.
Study end points
Primary study end point. Coronary occlusive collateral flow
relative to normal antegrade flow through the nonoccluded
coronary artery (CFI) was determined using coronary
pressure measurements. A 0.014-in pressure monitoring
angioplasty guidewire (PressureWire X Guidewire, Abbott,
Chicago, IL) was set at zero, calibrated, advanced through
the guiding catheter, and positioned in the distal part of the
vessel of interest (identical position at baseline and follow-up
examination). CFI was determined by simultaneous mea-
surement of mean Pao (mm Hg), the mean distal coronary
artery pressure during RCA balloon occlusion (Poccl, mm
Hg), and the mean CVP (mm Hg) (Figure 2) as measured
during the last 10 seconds of the balloon occlusion. CFI was
calculated as (Poccl − CVP) divided by (Pao − CVP).16 The
accuracy of pressure-derived CFI measurements in compar-
ison to ECG signs of myocardial ischemia during occlusion
and to absolute myocardial perfusion measurements has
been documented previously.16,17 The difference of CFI
during follow-up was calculated as CFI at follow-up
examination minus CFI at baseline examination.
Secondary study end points. Signs of myocardial ischemia were
obtained simultaneously with CFI measurements, that is,
during the same 1-minute ostial RCA balloon occlusion.
Myocardial ischemia was characterized by the presence
or absence of angina pectoris as interrogated immediately
after release of the angioplasty balloon occlusion at
baseline and follow-up examination. The parameter
change from baseline to follow-up examination was
categorized as follows: angina pectoris disappeared,
unchanged, or newly manifest. Additionally, ic ECG ST-
segment shift in mV was recorded during the same 1-
Figure 1
646 Patients assessed for eligibility
100 randomly assigned
51 allocated to permanent RIMA 
device occlusion
49 allocated to sham control 
treatment
2 lost to follow-up
1 missing follow-up data
48 available for intention-to-treat 
analysis
49 available for intention-to-treat 
analysis
208 Patients with written informed 
consent
49 with permanent RIMA device 
occlusion
49 underwent sham control 
treatment
2 with failed device implantation
108 peri-interventional exclusion:
53 no coronary artery 
disease
29 no RCA stenosis
4 coronary anatomy not 
suitable for balloon occlusion
5 withdrawal of consent
17 peri-interventional
exclusion criterion
438 excluded:
260 met an exclusion 
criterion
178 declined participation
Trial profile.
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Volume 230minute RCA balloon occlusions (Figure 2). The ic ECG
was obtained from the angioplasty pressure guidewire via
a cross-clamp to a precordial lead. Quantitative ic ECG ST-
segment shift was determined as the difference between
ic ECG ST-segment shift (elevation or depression obtained
at the J-point) during RCA occlusion minus ic ECG ST-segment shift immediately before RCA occlusion. The
change in ic ECG ST-segment shift was determined as
occlusive ic ECG ST-segment shift at follow-up minus ic
ECG ST-segment shift at baseline examination.
Exploratory study end points. As exploratory end points,
reactive hyperemia-induced fractional flow reserve
Figure 2
Upper panels: Angiograms (anteroposterior projection) of the right internal mammary artery (RIMA) before (left) and 6 weeks after its occlusion by
a vascular plug at the level of the right atrium (marked by a pigtail catheter). The pericardiacophrenic branch of the RIMA (arrows) is barely visible
at baseline. Its caliber is augmented at follow-up examination, and the pericardiacophrenic branch of the left IMA is also depicted. Lower panels:
Simultaneous recordings during the 1-minute ostial RCA balloon occlusion from the same patient of phasic and mean Pao (red curve), RCA Poccl
(black curve), CVP (blue curve; sequential recording during follow-up examination), and intracoronary ECG (bottom, black curve) as obtained
during baseline (left) and follow-up (right) examination. CFI = (Poccl − CVP)/(Pao − CVP).
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occlusion, and Canadian Cardiovascular Society (CCS)
class of angina was interrogated at baseline and follow-up
examination.Study protocol
Immediately following right radial artery sheath inser-
tion, 5,000 U of intravenous heparin plus 2 puffs of oral
isosorbide dinitrate was given. Following diagnostic
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Volume 230coronary angiography and at the start of the invasive
baseline and follow-up study procedure, all patients
received an additional 5000 U of heparin intravenously.
Among patients undergoing PCI of the left coronary
artery at baseline examination (nondeferred PCI of
stenotic lesions at an FFR ≤ 0.75), study end point
measurement in the RCA was always performed after
left coronary artery PCI. For RCA CFI and myocardial
ischemia measurements, an adequately sized angioplasty
balloon catheter was positioned in the ostial part of the
RCA, whereas the pressure guidewire was placed distally.
Coronary balloon inflation occurred at a pressure of 1-2
atm. Complete coronary occlusion was ascertained by
angiography. During the 1-minute occlusion, simulta-
neous Poccl, Pao, and CVP were recorded for the
calculation of CFI (Figure 2). During the entire proce-
dure, the ic ECG obtained from the guidewire was
recorded. Immediately following CFI measurement, the
patient was asked about the occurrence of angina
pectoris during RCA balloon occlusion. Directly after
RCA balloon deflation and without changing the sensor
wire position, reactive hyperemia, that is, postocclusive
FFR of the RCA, was obtained following RCA angiogra-
phy. FFR was equal to distal coronary pressure divided by
Pao.
In both groups, radiographic imaging of the RIMA was
performed using a 5F IMA catheter. In the placebo group,
the baseline examination ended after RIMA angiography.
In the verum group, a Radiofocus 0.032-in, 260-cm stiff
guidewire (Terumo Corporation, Tokyo, Japan) was
subsequently inserted into the IMA catheter and ad-
vanced with its tip to below the diaphragm. The IMA
catheter was then engaged in the RIMA until its tip
reached the level of the right atrium in anteroposterior
projection. Subsequently, an appropriately sized (4-5 mm
in diameter) Amplatzer vascular plug 4 (Abbott, Chicago,
IL) was inserted via the IMA catheter into the RIMA and
released at the level of the right atrium (Figure 2, top
panel). Invasive follow-up examinations at 6 weeks after
RIMA device occlusion consisted of RIMA radiographic
imaging in both groups and of identical study end point
measurements as described above.Statistical analysis
Sample size calculation was performed using a 2-sided
unpaired Student t test with the primary study end point
of CFI change during the 6-week follow-up study period
and was based on the following alternative hypothesis:
CFI change from baseline to follow-up examination is
higher in the verum than the placebo group. CFI change
was estimated to be +0.020 in favor of the verum group at
an SD of 0.035 yielding an effect size of 0.57,15 at an α
level of .05 and a power of 0.80. Accordingly, the
calculated sample size was equal to 100 patients (50 per
group). Between-group comparison of continuous demo-graphic, clinical, angiographic, and hemodynamic vari-
ables and study end point variables was performed by
unpaired Student t test. A χ2 test was used for
comparison of categorical variables among the study
groups. Intraindividual comparison of CFI, ic ECG ST-
segment shift, FFR, and heart rate obtained at baseline
versus follow-up examination was performed by a paired
Student t test. Statistical significance was defined at a P
level < .05. Continuous variables are given as mean and
SD.
Results
Fifty-one patients were randomly allocated to the RIMA
device occlusion group (verum group) and 49 patients to
the sham control group (placebo group) (Table I). A total
of 3 patients in the verum group were lost either to failed
study end point recording (n = 1) or to follow-up
examination (n = 2) (Figure 1).
Patient characteristics and clinical data at baseline
Patients were younger in the verum than those in the
placebo group (Table I). There were no statistically
significant differences between the groups regarding
gender, body mass index, CCS class of angina pectoris,
and cardiovascular risk factor prevalence (Table I).
Patients in the verum versus the placebo group had
suffered more prior myocardial infarction in another than
the RCA territory. Regarding cardiovascular medication,
there was no difference between the groups, except for
the less frequent use of calcium channel blockers and
diuretics in the verum than the placebo group (Table I).
Hemodynamic and coronary angiographic data at
baseline
There were no statistical differences between the
groups in heart rate, systemic blood pressure, left
ventricular end-diastolic pressure, left ventricular ejection
fraction, and central venous pressure (Table II). Central
venous pressure was directly obtained in 52 patients (26
each in both groups), and it was assumed equal to 5 mm
Hg in 48 patients. The number of coronary arteries with
stenotic lesions >50% was similar between the groups.
RCA quantitative percent diameter stenosis was similar in
both groups, and the number of chronic total RCA
occlusions was identical.
RCA PCI was deferred until follow-up examination
(after study end point measurement) in 96 patients; it was
performed for clinical reasons at baseline in 2 patients of
the verum group and in 2 patients of the placebo group.
Left coronary artery (LCA) PCI was deferred in 24 patients
each in the verum and placebo group (Table II). The LCA
vessel (left anterior descending artery [LAD] or left
circumflex coronary artery [LCX]) undergoing PCI or
the LCA stenosis severity did not differ between the
groups. Thrombolysis in Myocardial Infarction flow in
Table I. Patient characteristics at baseline examination.
Overall Verum Placebo P value
No. of patients 51 49
Patients lost to follow-up, n 3 3 0
Patient characteristics
Age 68 ± 12 66 ± 13 71 ± 9 .0286
Female gender, n (%) 12 (12) 10 (10) 14 (14) .49
Height (cm) 173 ± 8 173 ± 8 173 ± 7 .74
Weight (kg) 85 ± 17 87 ± 17 83 ± 16 .31
Body mass index (kg/m2) 28 ± 5 29 ± 5 28 ± 5 .20
Angina pectoris before intervention (%) 63 67 59 .44
Duration of angina pectoris (m) 5 ± 6 4 ± 5 6 ± 8 .42
CCS class of angina pectoris 2.25 ± 0.88 2.32 ± 0.84 2.17 ± 0.93 .50
Diabetes mellitus (%) 38 41 34 .50
Arterial hypertension (%) 80 78 81 .69
Current smoking (%) 20 19 20 .92
Cumulative pack years of cigarettes 41 ± 26 37 ± 23 45 ± 29 .36
Dyslipidemia (%) 87 86 88 .83
Family history for CAD (%) 28 28 29 .90
Prior myocardial infarction (%) 46 59 33 .0092
Medical treatment
Aspirin (%) 85 90 80 .24
Platelet inhibitor (%) 33 33 33 .94
Calcium channel-blocker (%) 31 20 43 .0122
β-Blocker (%) 65 71 59 .23
Nitrate (%) 17 14 20 .37
Oral anticoagulation (%) 17 22 12 .22
Statin (%) 79 84 74 .18
ACE inhibitor or ARB (%) 69 65 74 .34
Diuretics (%) 42 29 55 .0098
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
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December 2020patients with nondeferred LCA PCI was equal to 3 in all of
them. At baseline, RCA CFI tended to be lower in the
verum than the placebo group (Table II). At baseline,
angina pectoris during the same RCA occlusion occurred
more often, and ic ECG ST-segment shift was larger in the
verum than the placebo group (Table II).
Changes of coronary function and myocardial ische-
mia during follow-up
Primary study end point. At follow-up examination, RCA CFI
tended to be higher in the verum than the placebo group
(Table II). RCA CFI changed from 0.092 ± 0.078 at
baseline to 0.128 ± 0.066 at follow-up in the verum
group and from 0.123 ± 0.098 at baseline to 0.101 ±
0.077 at follow-up in the placebo group (Figure 3). RCA
CFI change during follow-up was significantly higher in
the verum than in the placebo group (Table II and Figure
4).
Secondary study end points. In the verum group, there was a net
decrease of 10 cases with angina pectoris during RCA
occlusion at follow-up versus baseline examination (net
increase of 6 cases in the placebo group) (Table II).
Angina pectoris during the 1-minute ostial RCA balloon
occlusion had disappeared more often at the follow-upexamination in the verum than in the placebo group (
Figure 5). Ic ECG ST-segment shift during the identical
RCA occlusion at follow-up was less pronounced in the
verum than the placebo group (Table II), and there was a
decrease in ic ECG ST-segment shift during follow-up in
the verum group, whereas the respective change was
positive during follow-up in the placebo group (Table II
and Figure 6).
Exploratory study end points. RCA FFR tended to increase in
the verum group, and it remained unchanged in the
placebo group (Table II). CCS class of angina pectoris at
follow-up was unchanged or worse in 20 and 30 patients
of the verum and placebo group, respectively, and it
improved in 28 and 19 patients of the verum and placebo
group, respectively (P = .0540).
Procedural feasibility of RIMA closure
RIMA device closure in the verum group was successful
in all but 3 patients (2 failed implantations, 1 aberrant
implantation into a RIMA side branch). One case of
proximal RIMA dissection occurred. These complications
were left untreated without sequelae. During the 6 weeks
of follow-up, all patients of the verum group remained
asymptomatic with regard to the RIMA device closure.
Table II. Invasive parameters at baseline and follow-up examination.
Overall Verum Placebo P value
Heart rate (beat/min) 75 ± 15 76 ± 17 73 ± 13 .34
Systolic blood pressure (mm Hg) 123 ± 24 121 ± 23 125 ± 24 .40
Diastolic blood pressure (mm Hg) 63 ± 11 64 ± 12 61 ± 10 .15
Left ventricular end-diastolic pressure (mm Hg) 11 ± 7 11 ± 7 11 ± 7 .79
Left ventricular ejection fraction (%) 58 ± 10 58 ± 10 58 ± 10 .89
CVP (mm Hg) 6 ± 3 6 ± 3 6 ± 3 .41
Coronary angiographic parameters at baseline
No. of diseased vessels 2.31 ± 0.75 2.35 ± 0.72 2.27 ± 0.79 .59
RCA percent diameter stenosis 48 ± 23 49 ± 25 47 ± 23 .70
RCA chronic total occlusion, n 8 4 4 .92
RCA PCI deferred, n (%) 96 (96) 49 (96) 47 (96) .89
LCA PCI deferred, n (%) 48 (48) 24 (47) 24 (49) .92
LCA treated by PCI .56
LAD, n 36 19 17
LCX, n 25 10 15
LAD percent diameter stenosis 55 ± 20 55 ± 21 55 ± 23 .82
LCX percent diameter stenosis 44 ± 17 44 ± 15 44 ± 22 .95
RCA functional outcome parameters at baseline and follow-up
RCA CFI @ baseline 0.108 ± 0.089 0.092 ± 0.078 0.123 ± 0.098 .09
RCA CFI @ follow-up 0.115 ± 0.073 0.128 ± 0.066 0.101 ± 0.077 .07
Delta CFI (follow-up minus baseline) +0.007 ± 0.088 +0.036 ± 0.068 −0.021 ± 0.097 .0011
Angina pectoris during ostial RCA occlusion @ baseline, n 52 32 20 .0260
Angina pectoris during ostial RCA occlusion @ follow-up, n 48 22 26 .54
New angina pectoris during ostial RCA occlusion @ follow-up, n 14 4 10
Ic ECG ST-shift during ostial RCA occlusion @ baseline (mV) 0.438 ± 0.465 0.525 ± 0.555 0.365 ± 0.350 .07
Ic ECG ST-shift during ostial RCA occlusion @ baseline (mV) 0.462 ± 0.496 0.352 ± 0.365 0.567 ± 0.570 .0312
Delta ic ECG ST-shift (follow-up minus baseline) +0.024 ± 0.462 −0.173 ± 0.472 +0.202 ± 0.515 .0004
RCA FFR @ baseline 0.902 ± 0.096 0.900 ± 0.094 0.902 ± 0.097 .72
RCA FFR @ follow-up 0.908 ± 0.099 0.917 ± 0.065 0.896 ± 0.123 .29
Delta RCA FFR (follow-up minus baseline) +0.005 ± 0.083 +0.014 ± 0.079 −0.011 ± 0.082 .11
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follow-up revealed incomplete occlusion at the device in
16 of 49 cases. Among patients with incomplete
occlusion, delta CFI was not statistically different from
that in patients with complete device occlusion
(+0.039 ± 0.058 and +0.028 ± 0.075, respectively; P =
.70).Discussion
The present randomized controlled trial found perma-
nent RIMA device occlusion superior to RIMA sham
treatment in terms of augmented RCA collateral function
as obtained during a brief artificial ostial RCA occlusion
6 weeks after study intervention. Improved RCA supply
in the RIMA occlusion group was reflected by more
frequent angina pectoris relief and less severe ECG signs
of myocardial ischemia during the same systematic 1-
minute RCA occlusion.
Incomplete coronary revascularization
The results of the present trial offer a new and
sustainable treatment option for patients with incompletecoronary revascularization (multivessel CAD, chronic
total occlusion of the RCA following unsuccessful
interventional treatment, no-option surgical candidates
18) and, as such, for those with refractory angina pectoris.
Refractory angina pectoris is defined as angina pectoris
of more than 3 months’ duration associated with
reversible myocardial ischemia in the context of CAD
which cannot be controlled by medical, coronary
interventional, or surgical therapy.19 Hence, the terms
incomplete revascularization and refractory angina
pectoris are closely related, whereby the former concerns
a larger population because not all patients with
incomplete revascularization suffer from angina pectoris.
The prevalence of refractory angina amounts to 10%-12%
of patients with chronic CAD,20 and more than 25% of
patients undergoing coronary angiography have been
reported to receive incomplete revascularization.7 Mor-
tality of patients with refractory angina as well as those
with incomplete revascularization is slightly elevated at
4%-5% per year.7 , 20 Since the early 1990s, many
therapeutic concepts have been proposed for the
treatment of refractory angina pectoris such as therapeu-
tic angiogenesis,21 arteriogenesis,22 stellate ganglion
Figure 3
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mic preconditioning,24 lower-limb external diastolic
counterpulsation,25 and coronary sinus reducer stent
implantation.26 Although some of these treatment
modalities have not undergone sound efficacy testing,
others have done so but proven inefficacious (angiogen-
esis).21 Furthermore and except for coronary sinus
reducer treatment, the other therapeutic options are
not sustainable. They require repetitive applications for a
lasting effect, thus reducing the tolerability of a proce-
dure, especially if it is as strenuous and time-consuming
as, for example, external counterpulsation with its daily 1-
hour sessions.
In comparison, in situ anatomical connections between
the IMAs and the coronary circulation are the basis for a
sustainable source of myocardial blood supply with the
potential of partially substituting the diseased coronary
circulation.12 In principle, this applies also to the
extracardiac source of collateral connections between
the bronchial artery and the RCA, respectively, the left
circumflex coronary artery (LCX).27 However, these
anastomoses are less accessible and less explored than
the IMA–coronary artery network.
Extracardiac coronary artery supply
In contrast to the human intercoronary collateral
arterioles and arteries called endomural coronary
anastomoses,22 the extracardiac coronary arterial anas-
tomoses have received much less attention even though
they have been known for a long time in healthy and
diseased individuals.10 Hudson et al discovered extra-
cardiac anastomoses unintentionally while injecting the
coronary circulation with ink and observing the dye
dispersing to sites such as the pericardium; the pericar-
dial reflections of the great vessels; and anteriormediastinal, phrenic, intercostal, esophageal, and peri-
cardiacophrenic arterial branches.10 Moberg et al later
observed direct connections between these mediastinal
arterial sources and atrial branches of the coronary
circulation.11 The pericardiacophrenic arterial branch is
the first or second branch of the internal mammary
arteries taking off the proximal IMAs at the second
intercostal space. On angiography, it is easily recogniz-
able by its unique motion pattern simultaneous to the
heart beat. Case reports have provided structural
angiographic evidence of arterial connections between
the pericardiacophrenic artery but also of other IMA
branches and the coronary arteries.27,28
Because of the anatomical connection to both the
upper and lower limb arterial circulation (subclavian
arteries and external iliac arteries, respectively), the
supply regions of the IMAs and their native, that is,
nonligated, side branches are not at risk for ischemia. In
fact, collateral perfusion pressure downstream of a
proximal IMA balloon occlusion amounts to approxi-
mately 80% of normal perfusion pressure during IMA
patency (own data). This physiologic piece of evidence
explains the relatively low number of ischemic events
following IMA coronary artery bypass grafting with the
exception of hampered sternal wound healing as a
consequence of extensive IMA side branch ligation.
Before the advent of coronary bypass surgery, the liga-
tion of the IMAs aiming at redirecting blood flow to the
pericardiacophrenic branch was introduced as a treat-
ment concept for angina pectoris by Fieschi.29 Following
initial documentation of clinical success,30 surgical IMA
ligation has been reported inefficacious based on 2 very
small (totaling 35 patients) but sham-controlled clinical
trials,31,32 the publication of which together with the
advent of the heart-lung machine closed this option of
Figure 4
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Volume 230myocardial revascularization almost entirely. The physi-
cal basis of action of IMA ligation, flow diversion toward
its side branches connecting to the heart, persisted only
in the Vineberg procedure with its direct implantation of
the disconnected IMAs into the freely exposed
myocardium.
Permanent RIMA occlusion
Recently, there have been 2 clinical investigations
supporting the physical concept of enhanced myocardial
perfusion by increased resistance to IMA flow down-
stream of its pericardiacophrenic branch. First, tempor-
ary distal IMA with simultaneous ostial coronary arteryballoon occlusion in 120 patients with CAD has found
ischemia-reducing, enhanced extracardiac coronary ar-
tery supply via natural IMA bypasses.14 Specifically, the
CFI difference as obtained with versus without IMA
occlusion was consistently positive during left IMA with
LAD occlusion and during RIMA with RCA occlusion:
+0.033 ± 0.044 and +0.025 ± 0.027.14 Second, perma-
nent RIMA device occlusion has been shown feasible and
potentially efficacious on RCA occlusive, that is, collater-
al, function and on simultaneous signs of myocardial
ischemia in an open, proof-of-concept study.15 The
rationale for selecting the RIMA rather than the LIMA to
undergo permanent occlusion for feasibility testing has
Figure 6
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Individual changes of ic ECG ST-segment shifts (vertical axis) between baseline and follow-up examination for patients in the verum (filled circles,
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December 2020been to largely minimize the risk of wasting a surgical
bypass. At our institution, RIMA coronary artery bypass
grafts account for 5%-8% of all coronary grafts. In
addition, the distal occlusion site at the level of the
right atrium would still allow the RIMA to be grafted onto
the RCA.
The present randomized controlled and double-blind
trial has been the rational consequence of the above-
mentioned open-label study on the feasibility of perma-
nent IMA occlusion.15 Except for the 2 mentioned
pathophysiologic studies on the topic of IMA occlusion,
there have been no data from the literature allowing
direct comparison of the primary study end point, that is,
quantitative RCA collateral function. Considering the
increase in RCA CFI of +0.025 ± 0.027 during temporary
RIMA balloon occlusion,14 the respective value of
+0.036 ± 0.068 in the present trial is slightly higher
though in a similar range. During 6 weeks of permanent
RIMA occlusion, RCA CFI increase in our uncontrolled
study amounted to +0.067 ± 0.094,15 the difference of
which to the present trial may be partly explained by the
larger fraction of 16/48 patients showing incomplete
RIMA occlusion when compared to 11/50 patients in the
proof-of-concept study. Notwithstanding, permanent
RIMA device occlusion in the present trial still proved
to be efficacious on all predefined outcome parameters in
spite of incomplete closure in one third of the verum
group. In the scientific methodologic sense, incomplete
RIMA occlusion tends to preserve the trial's null
hypothesis of no treatment effect and as such strongly
supports the trial results. Angina pectoris during the brief
ostial RCA occlusion (1 of the secondary end points
indicative of myocardial ischemia) disappeared more
frequently in the verum than the placebo group, the
result of which challenges the findings of the underpow-
ered though sham-controlled IMA ligation studies men-tioned above.31 , 32 The importance of applying a
controlled ischemic stimulus with identical duration
and size of ischemia for assessing the symptom of angina
pectoris becomes evident even within our trial when
considering that the CCS class of angina was affected by
RIMA occlusion to a lesser though still positive degree.
Conversely, to test the effect of RIMA occlusion on a less
systematically obtained primary outcome parameter such
as the more authentic CCS class of angina would have
required a more sizeable study population. The results of
the other, simultaneously obtained quantitative parame-
ter for gauging myocardial ischemia, ic ECG ST-segment
shift, mirror the effect of RIMA occlusion on angina
pectoris. The theoretical possibility that these consistent-
ly alleviated signs of myocardial ischemia would be the
effect of remote ischemic preconditioning (by the RIMA
vascular plug) is dismissible because RIMA occlusion does
not cause ischemia due to its supply from the upper and
lower extremity circulation. Also, the effect of RIMA
occlusion on signs of myocardial ischemia was associated
with augmented RCA collateral supply.
Study limitations
Incomplete coronary revascularization was not an
eligibility criterion for the present study, although IMA
occlusion conceptually aims at this patient population.
However, at this early stage of controlled efficacy testing,
patients with mild coronary atherosclerosis were also
included, thus allowing ostial RCA balloon occlusion for
end point measurement with technical ease, while at the
same time assessing the effect of RIMA occlusion in a less
symptomatic population, thus tending to conserve the
trial's null hypothesis. According to the same methodo-
logic principle, technical failure of device implantation in
3 patients supports the positive study findings because
data were analyzed per intention to treat. Failure of RIMA
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Volume 230device implantation in those cases occurred for safety
reasons to prevent long intervention times in the
proximity of the neck vessels. Along the same methodo-
logic line, the relatively short follow-up duration of
6 weeks versus, for example, a longer period of 6 months
most likely supported the trial's null hypothesis of no
treatment effect of RIMA occlusion.33 For clinical
reasons, a very small number of 4 patients (2 in each
group) underwent PCI of the RCA at baseline. The
concomitant coronary hemodynamic changes reduced
the primary study end point CFI in both groups, thus
having no net effect on the study results. Despite the
randomized allocation of study participants to the
treatment groups, a few clinical variables were unequally
distributed: age, prior myocardial infarction in non-RCA
territory, and treatment with calcium channel blockers
and diuretics. Statistically (multivariate regression analy-
sis), the unbalanced distribution of these covariables did
not affect the study outcomes. The present trial's results
may not be representative for nonwhite people and for
the female gender.Conclusions
Permanent RIMA device occlusion augments right
coronary artery supply to the effect of diminishing
clinical and electrocardiographic signs of myocardial
ischemia during a brief controlled coronary occlusion.Disclosures
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